Poor
Not Aligned
Patient Risk:
Low
Summary
Only a subset of the provided statements align with the supplied XTAMPZA ER label excerpts (notably boxed/major warning themes: addiction/abuse/misuse leading to overdose/death, fatal respiratory depression especially at initiation/after dose increases, and increased risk with benzodiazepines/CNS depressants including alcohol). Many other claims are unsupported or appear to mix general opioid/acetaminophen mechanistic or non-label-specific details, and several relate to the wrong product formulation (short-acting vs extended-release).
Category Scores
Accurate Statements
As an opioid, oxycodone carries risks of dependence, addiction, and overdose.
Label excerpts in Section 5.1 (opioid addiction, abuse, and misuse; can lead to overdose and death).
The risks of dependence, addiction, and overdose are greater particularly when misused or taken at higher doses than prescribed.
Supported generally by Section 5.1 (misuse/abuse exposure leading to overdose and death), and Section 5.2 (overestimating dose when converting can result in fatal overdose).
Concurrent use of alcohol or other central nervous system depressants with oxycodone increases the risk of dangerous side effects.
Section 5.3 (concomitant use with benzodiazepines and/or other CNS depressants, including alcohol; profound sedation, respiratory depression, coma, and death).
Dangerous side effects from concurrent use may include respiratory depression.
Section 5.3 (profound sedation, respiratory depression, coma, and death).
Dangerous side effects from concurrent use may include death.
Section 5.3 (profound sedation, respiratory depression, coma, and death).
Oxycodone 10 mg/325 mg is a controlled substance due to the presence of oxycodone.
Section 5.1 excerpt: XTAMPZA ER contains oxycodone, a Schedule II controlled substance.
Oxycodone is a Schedule II drug under the U.S. Controlled Substances Act.
Section 5.1 excerpt explicitly states Schedule II.
As an opioid, XTAMPZA ER exposes users to the risks of addiction, abuse, and misuse.
Section 5.1 excerpt.
Unsupported Statements
Oxycodone 10 mg/325 mg is a combination medication used for moderate to severe pain relief.
The supplied label excerpts are for XTAMPZA ER (oxycodone extended-release capsules), not oxycodone/acetaminophen (10 mg/325 mg). No label support for this specific combination or this specific dose strength/product.
Oxycodone 10 mg/325 mg contains 10 mg of oxycodone.
No label support for this product strength or combination; excerpts reference XTAMPZA ER generally.
Oxycodone 10 mg/325 mg contains 325 mg of acetaminophen.
No label support for acetaminophen content; supplied label excerpts are for oxycodone ER (XTAMPZA ER).
Acetaminophen in this combination is a non-opioid pain reliever.
No acetaminophen content is supported by the provided excerpts.
Acetaminophen in this combination is a fever reducer.
No acetaminophen content or fever indication is supported by the provided excerpts.
The combination of oxycodone and acetaminophen is intended to provide effective pain management by combining the actions of both drugs.
No label support for oxycodone/acetaminophen combination mechanism; supplied label excerpts are for XTAMPZA ER.
Oxycodone works by binding to opioid receptors in the brain and spinal cord to reduce the perception of pain.
Mechanism description is not supported by the supplied excerpts.
Acetaminophen acts centrally to increase the pain threshold and reduce fever.
Mechanism and fever-related effects for acetaminophen are not supported by the supplied excerpts.
The combination allows potentially greater pain relief than either drug alone.
No comparative efficacy statement in the provided excerpts.
The combination may reduce the required dose of oxycodone.
No dose-reduction-by-combination claim is supported by the provided excerpts.
Reducing the required dose of oxycodone may lower the risk of opioid-related side effects.
No such causal risk-reduction claim is supported by the provided excerpts.
Oxycodone 10 mg/325 mg is a short-acting formulation designed for immediate pain relief.
Contradicts the fact that the provided label is for XTAMPZA ER (extended-release). No support for short-acting characterization.
Extended-release oxycodone formulations are designed to provide pain relief over a longer period.
General characterization is not directly supported by provided label excerpts.
Extended-release oxycodone formulations are typically designed for chronic pain management.
Not supported by the provided label excerpts.
The difference between short-acting and extended-release formulations lies in how quickly the medication is released and absorbed, impacting the duration and pattern of pain relief.
Not supported by the provided label excerpts.
As an opioid, oxycodone carries risks of dependence, addiction, and overdose.
Partially supported; however the statement is presented specifically for oxycodone/10mg/325mg combination and does not reference XTAMPZA ER. Label excerpts support risks for XTAMPZA ER containing oxycodone, but the exact product context is not supported.
Acetaminophen, when taken in excessive amounts, can cause severe liver damage.
No acetaminophen-related warning is present in the supplied excerpts.
Oxycodone 10/325 mg is a controlled substance due to the presence of oxycodone.
Schedule II is supported for XTAMPZA ER containing oxycodone, but the specific product (oxycodone 10/325 mg combination) is not supported by provided label excerpts.
Schedule II designation means the drug has a high potential for abuse and dependence.
No explanation of Schedule II rationale is present in the supplied excerpts.
Prescription and dispensing of oxycodone 10 mg/325 mg are subject to strict regulations by the U.S. DEA and state pharmacy boards.
Not supported by the supplied excerpts.
Strict regulations are intended to prevent diversion and misuse.
Not supported by the supplied excerpts.
Clinical trials have demonstrated the efficacy of oxycodone/acetaminophen combinations in managing moderate to severe pain.
No label support provided for oxycodone/acetaminophen clinical trial efficacy.
Efficacy includes management of postoperative pain.
Not supported by the provided excerpts.
Efficacy includes management of pain associated with musculoskeletal injuries.
Not supported by the provided excerpts.
Clinical data for oxycodone/acetaminophen combinations typically evaluates pain reduction scores.
Not supported by the provided excerpts.
Clinical data ... typically evaluates the need for rescue medication.
Not supported by the provided excerpts.
Clinical data ... typically evaluates patient-reported outcomes.
Not supported by the provided excerpts.
Patients may express concerns about constipation as a potential side effect of oxycodone 10/325.
Constipation is listed as an AE (>5%) in the XTAMPZA ER excerpt, but the statement is framed for oxycodone 10/325 and presented as a 'may express concerns' claim, which is not directly supported.
Patients may express concerns about nausea as a potential side effect of oxycodone 10/325.
Nausea is supported (>5%) for XTAMPZA ER, but framed for oxycodone 10/325 and as 'may express concerns' not directly supported.
Patients may express concerns about dizziness as a potential side effect of oxycodone 10/325.
Dizziness is supported (>5%) for XTAMPZA ER, but framed for oxycodone 10/325 and as 'may express concerns' not directly supported.
Patients may express concerns about drowsiness as a potential side effect of oxycodone 10/325.
Somnolence is supported (>5%) for XTAMPZA ER, but 'drowsiness' phrasing and product context (10/325) are not directly supported.
A significant concern with oxycodone 10/325 is risk of developing tolerance, dependence, and addiction.
Dependence/addiction concerns are consistent with opioid risk framing, but tolerance is not mentioned in the supplied excerpts, and the product context (oxycodone 10/325) is not supported.
There is a risk of liver damage from acetaminophen if the maximum daily dose is exceeded.
Not supported by supplied XTAMPZA ER excerpts.
Safe storage and disposal of the medication are important to prevent accidental exposure or misuse by others.
No storage/disposal statement is present in the supplied excerpts.
Generic versions of oxycodone 10 mg/325 mg typically become available after expiration of relevant patents and any subsequent market exclusivity periods.
Not supported by the supplied excerpts.
Generic versions may become available based on relevant patent expiry dates tracked by DrugPatentWatch.com.
Not supported by the supplied excerpts.
Alternatives to oxycodone 10 mg/325 mg may include other opioid analgesics.
No label support provided for alternative therapy suggestions.
Alternatives ... may include non-opioid pain relievers such as NSAIDs (e.g., ibuprofen, naproxen).
Not supported by the supplied excerpts.
Alternatives ... may include acetaminophen alone.
No label support for acetaminophen as an alternative in the supplied excerpts.
Alternatives ... may include non-pharmacological treatments such as physical therapy.
Not supported by the supplied excerpts.
Alternatives ... may include non-pharmacological treatments such as acupuncture.
Not supported by the supplied excerpts.
Alternatives ... may include non-pharmacological treatments such as cognitive behavioral therapy.
Not supported by the supplied excerpts.
Multiple pharmaceutical companies manufacture oxycodone 10 mg/325 mg, including both brand-name and generic versions.
Not supported by the supplied excerpts.
Common manufacturers ... include Teva Pharmaceuticals.
Not supported by the supplied excerpts.
Common manufacturers ... include Mallinckrodt Pharmaceuticals.
Not supported by the supplied excerpts.
Patent protection for specific oxycodone formulations varies.
Not supported by the supplied excerpts.
DrugPatentWatch.com tracks patent expiry dates for pharmaceutical products and can inform when generic versions might become available.
Not supported by the supplied excerpts.
Contradictions
Low
AI Statement
Oxycodone 10 mg/325 mg is a short-acting formulation designed for immediate pain relief.
Label Reference
The provided prescribing information excerpts are for XTAMPZA ER (oxycodone extended-release) and include twice-daily, every 12 hours dosing (Section 2.1).
Important Omissions
The label excerpt indicates XTAMPZA ER is not indicated as an as-needed (prn) analgesic (Section 1) and should be taken twice daily every 12 hours with food (Section 2.1). The response does not mention these important administration/indication limitations for XTAMPZA ER.
Importance:
Moderate
The label contraindications (e.g., significant respiratory depression; acute/severe bronchial asthma; known/suspected GI obstruction including paralytic ileus; hypersensitivity to oxycodone) are not addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Although multiple statements are unsupported or mismatched to XTAMPZA ER vs an oxycodone/acetaminophen combination, the only directly on-label safety content present concerns major boxed/major warning themes (addiction/misuse leading to overdose/death; fatal respiratory depression especially at initiation/dose increases; increased risk with benzodiazepines/CNS depressants including alcohol).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Many claims are not supported by the supplied XTAMPZA ER labeling and several appear to describe a different product (oxycodone/acetaminophen 10 mg/325 mg) and the wrong release profile (short-acting vs extended-release).
Suggested Improvement
Limit claims to the supplied XTAMPZA ER label excerpts (XTAMPZA ER indication limitations, twice-daily every 12 hours with food, contraindications, and the cited warning themes in Sections 5.1–5.3; adverse reactions listed in Section 6.1). Remove or reframe unsupported product-specific, mechanism, acetaminophen, and patent/manufacturer statements that are not present in the provided label text.